David Dornan
Overview
Explore the profile of David Dornan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ackerman S, Pearson C, Gregorio J, Gonzalez J, Kenkel J, Hartmann F, et al.
Nat Cancer
. 2022 Feb;
2(1):18-33.
PMID: 35121890
Innate pattern recognition receptor agonists, including Toll-like receptors (TLRs), alter the tumor microenvironment and prime adaptive antitumor immunity. However, TLR agonists present toxicities associated with widespread immune activation after systemic...
2.
Jenkins R, Aref A, Lizotte P, Ivanova E, Stinson S, Zhou C, et al.
Cancer Discov
. 2017 Nov;
8(2):196-215.
PMID: 29101162
systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination...
3.
Willumsen N, Bager C, Leeming D, Smith V, Christiansen C, Karsdal M, et al.
Cancer Med
. 2014 Jul;
3(5):1136-45.
PMID: 25044252
Extracellular matrix (ECM) proteins, such as collagen type I and elastin, and intermediate filament (IMF) proteins, such as vimentin are modified and dysregulated as part of the malignant changes leading...
4.
Weisser M, Yeh R, Duchateau-Nguyen G, Palermo G, Nguyen T, Shi X, et al.
Blood
. 2014 Jun;
124(3):420-5.
PMID: 24916506
Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from...
5.
Willumsen N, Bager C, Leeming D, Smith V, Karsdal M, Dornan D, et al.
BMC Cancer
. 2013 Nov;
13:554.
PMID: 24261855
Background: Pancreatic cancer (PC) is an aggressive disease with an urgent need for biomarkers. Hallmarks of PC include increased collagen deposition (desmoplasia) and increased matrix metalloproteinase (MMP) activity. The aim...
6.
de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz G, Burford B, et al.
BMC Genomics
. 2013 Sep;
14:643.
PMID: 24059244
Background: This study focuses on the analysis of miRNAs expression data in a cohort of 181 well characterised breast cancer samples composed primarily of triple-negative (ER/PR/HER2-negative) tumours with associated genome-wide...
7.
Hwang M, Yu N, Stinson S, Yue P, Newman R, Allan B, et al.
PLoS One
. 2013 Jun;
8(6):e66502.
PMID: 23776679
The epithelial-to-mesenchymal transition (EMT) is a highly conserved physiological program involved in development and tissue repair; however, its aberrant activation has been implicated in accelerating the progression of a variety...
8.
Li D, Poon K, Yu S, Dere R, Go M, Lau J, et al.
Mol Cancer Ther
. 2013 Apr;
12(7):1255-65.
PMID: 23598530
Antibody-drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S...
9.
Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, et al.
Blood
. 2013 Mar;
121(18):3650-7.
PMID: 23525797
In chronic lymphocytic leukemia (CLL) patients, disruptions of the TP53 tumor suppressor pathway by 17p13 deletion (del17p), somatic TP53 mutations, or downregulation of microRNA-34a have been associated with a poor...
10.
Shi X, Dornan D
Oncoimmunology
. 2012 Jun;
1(1):83-85.
PMID: 22720219
In the context of the clinical development of a CD40-stimulatory monoclonal antibody for the treatment of B-cell cancers, a tumor mRNA-based gene signature reflecting CD40 signaling pathway activation status was...